Traders bought shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) on weakness during trading on Monday. $93.31 million flowed into the stock on the tick-up and $55.86 million flowed out of the stock on the tick-down, for a money net flow of $37.45 million into the stock. Of all stocks tracked, Regeneron Pharmaceuticals had the 22nd highest net in-flow for the day. Regeneron Pharmaceuticals traded down ($1.30) for the day and closed at $366.96
A number of analysts have commented on REGN shares. UBS Group reduced their price objective on Regeneron Pharmaceuticals from $535.00 to $500.00 and set a “buy” rating for the company in a research report on Thursday, September 21st. Oppenheimer restated a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, September 27th. Piper Jaffray Companies restated an “overweight” rating and set a $540.00 target price on shares of Regeneron Pharmaceuticals in a research report on Friday, September 29th. SunTrust Banks restated a “hold” rating and set a $435.00 target price on shares of Regeneron Pharmaceuticals in a research report on Monday, October 2nd. Finally, Zacks Investment Research downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 4th. Two research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $471.11.
The company has a market cap of $39,780.00, a P/E ratio of 33.62, a P/E/G ratio of 1.41 and a beta of 1.52. The company has a current ratio of 3.63, a quick ratio of 3.07 and a debt-to-equity ratio of 0.12.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.83 by $0.16. The company had revenue of $1.50 billion during the quarter, compared to analysts’ expectations of $1.45 billion. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. The business’s revenue for the quarter was up 23.0% on a year-over-year basis. During the same period last year, the firm earned $3.13 EPS. analysts predict that Regeneron Pharmaceuticals Inc will post 13.55 EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. National Asset Management Inc. grew its stake in shares of Regeneron Pharmaceuticals by 3.1% during the second quarter. National Asset Management Inc. now owns 856 shares of the biopharmaceutical company’s stock worth $421,000 after purchasing an additional 26 shares during the period. Suntrust Banks Inc. grew its stake in shares of Regeneron Pharmaceuticals by 1.9% during the second quarter. Suntrust Banks Inc. now owns 3,194 shares of the biopharmaceutical company’s stock worth $1,568,000 after purchasing an additional 59 shares during the period. Thrivent Financial For Lutherans grew its stake in shares of Regeneron Pharmaceuticals by 2.2% during the second quarter. Thrivent Financial For Lutherans now owns 2,850 shares of the biopharmaceutical company’s stock worth $1,400,000 after purchasing an additional 60 shares during the period. Rafferty Asset Management LLC grew its stake in shares of Regeneron Pharmaceuticals by 2.9% during the second quarter. Rafferty Asset Management LLC now owns 3,111 shares of the biopharmaceutical company’s stock worth $1,528,000 after purchasing an additional 87 shares during the period. Finally, Intellectus Partners LLC grew its stake in shares of Regeneron Pharmaceuticals by 5.6% during the second quarter. Intellectus Partners LLC now owns 1,749 shares of the biopharmaceutical company’s stock worth $859,000 after purchasing an additional 93 shares during the period. 66.63% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: “Traders Buy Regeneron Pharmaceuticals (REGN) on Weakness” was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://ledgergazette.com/2018/01/17/traders-buy-regeneron-pharmaceuticals-regn-on-weakness.html.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.